SlideShare a Scribd company logo
RATES AND TIMING OF
SUBSEQUENT AMPUTATION
AFTER INITIAL MINOR
AMPUTATION
Introduction
Major amputation is a significant concern for patients who have undergone a minor
amputation due to diabetes mellitus (DM) and/or peripheral artery disease (PAD).
Fear a major amputation than to fear death (Wukich et al).
Only 55% of patients with a below-the-knee amputation and 45% of those with an
above-the-knee amputation report a good functional outcome.
The rate of major amputation after initial minor amputation varies from 14% to 35%
METHODS
A retrospective cohort study using all-payer statewide data
from OSHPD between 2005 and 2013.
The Institutional Review Boards for the California Health and
Welfare Agency (Committee for the Protection of Human
Subjects) approved this study and waived consent given the
retrospective nature of the study.
Database
The California OSHPD database captures all nonfederal inpatient hospitalizations.
The OSHPD collects data from all emergency departments and from eligible ambulatory
surgery centers
Nonfederal hospitals account for 96% of the hospitals in California. Records for each
patient in the OSHPD database are linked through an encrypted Social Security Number
called the Record Linkage Number.
Within the PDD and EDD, medical diagnoses and procedures were coded
using (ICD-9-CM).
All patients admitted to the hospital are captured as a part of the PDD and
had their therapy administered on an inpatient basis.
Patient was first evaluated in the emergency department and discharged.
Patients that initially presented to the emergency room are part of the
EDD.
The ASD procedures are coded using Current ProcedureTerminology code
The primary end point was major amputation, defined as a below knee or an above knee
amputation and was identified by ICD-9-CM codes.
The secondary end points include time to major amputation, repeat minor amputation,
time to repeat minor amputation, overall mortality, time to death, and the combined
outcome of amputation or death. Additional analysis was performed to examine how
timing of revascularization and location of initial presentation were associated with risk of
subsequent major amputation.
Comorbidity data
The Elixhauser comorbidity
software was used to define
comorbidities; DM and PAD
were excluded
Additional comorbid conditions
were captured using data provided
by the secondary diagnosis codes,
such as coronary artery disease,
congestive heart failure, renal
failure, and tobacco use
StatisticalAnalysis
For categorical variables, the three distinct disease groups were compared using the X2 test.
Frequencies and percentages were used for categorical variables.
Medians and interquartile ranges (IQRs) were used to describe skewed continuous data.
Means and standard deviations were used to describe normally distributed continuous variables.
Rates were determined by the number of patients who underwent major amputation divided by the number of
patients in each disease category and reported as a percentage.
For continuous variables, the groups were compared using a
pairwise t-test with Bonferroni adjustment.
Competing risk Cox proportional hazards analysis was used to
evaluate for risk factors associated with major amputation.
All analyses were performed using R Programming for
Statistical Analysis (The R Foundation,Vienna, Austria).
A P value of less than .05 was considered statistically
significant.
Baseline characteristics varied significantly between the three disease groups (Table I).
Patients in the combined PAD/DM group had more comorbidities with a higher prevalence of
coronary artery disease, congestive heart failure, and renal failure.
The patients with DM alone tended to be younger with an average age of 62 6 13 years old,
whereas there were more smokers (PAD 1⁄4 20%, DM 1⁄4 10%, PAD/DM 1⁄4 10%; P < .001) and
white patients (PAD 1⁄4 52% DM 1⁄4 40%, PAD/DM 1⁄4 35%; P < .001) in the PAD only group.
Patients with DM alone were the least likely to undergo any revascularization procedure during
the study period (DM 1⁄4 75% no revascularization, PAD 1⁄4 64%, PAD/DM 1⁄4 63%; P < .001).
Rate of subsequent amputation
The overall rate of major amputation in the cohort was 5.1% (n 1⁄4
594) and the rate of repeat minor amputation was 14.5% (n 1⁄4
1676).
Patients with combined PAD/DM were more likely to undergo
major amputation (n 1⁄4 327 [6.3%]) compared with patients with
DM (n 1⁄4 223 [5.2%]) or PAD alone (n 1⁄4 44 [2.1%]; P < .001).
Patients in the PAD/DM group were also more likely to require a
second minor amputation as well (PAD/DM 1⁄4 16%, DM 1⁄4 12.2%,
PAD 1⁄4 15.2%; P < .001;Table II).
Time to subsequent amputation.
The median time to a second minor amputation was 4.9 months (IQR, 1.8-14.7 months).
Patients with DM had a longer time be- tween the initial minor amputation and the
second mi- nor amputation (5.9 months; IQR, 2.1-17 months; P < .01), whereas patients
with PAD and PAD/DM were more likely to require a second minor amputation sooner,
with both groups having a median time of 4.5 months (PAD IQR, 1.5-15 months; PAD/DM
IQR, 1.8-13 months).The median time to major amputation for all patients was 12.9
months (IQR, 5.4-27.6 months).There was no statistically significant difference in time
Major amputation between patients in the three groups, but patients with PAD only
had a median time to major amputation of 8.6 months (IQR, 4.2-23.4 months)
compared with patients with DM at 14.1 (IQR, 5.6-33.1 months) and PAD/DM at
13.3 months (IQR, 5.5- 25.3; Table II).
Mortality
• The overall mortality for the entire cohort was high at 46.7% (Fig 2). Patients in the DM
only group had the lowest mortality at 41% compared with 52% in the PAD only group
and 49% in the combined PAD/DM group. As shown inTable II, the median time to
death for patients in the DM only group was longest at 17.6 months (1.5 years; IQR, 7.1-
35.3 months). Patients with PAD had the shortest time to death at 10 months (0.8
years; IQR, 4.4-25.4 months).The median time to death for patients with combined
PAD/DM was 13.3 months (1.1 years; IQR, 5.3-32.6 months; P < .001).
Revascularization
• In 63% of patients with known PAD and 64% of patients with PAD/DM, no
revascularization was attempted before subsequent major amputation was performed.
After adjusting for age, race, sex, payer status, and associated comorbid conditions,
there was
CONCLUSIONS
Despite these limitations, the data illustrate that patients with lower extremity wounds
who require any amputation have multiple comorbidities and have a high mortality rate.
A number of these patients, especially those with combined PAD and DM, will require a
subsequent major amputation in approximately 1 year after their initial minor amputation.
Furthermore, the lower risk of subsequent limb loss in patients who were revascularized
before another minor amputation and those who were evaluated and treated entirely on
an outpatient basis suggests that there is a benefit in early diagnosis and therapy.
Future work should aim to evaluate the effect of time to treatment on patient outcomes.

More Related Content

What's hot

Hysterectomy for benign conditions in a university hospital in
Hysterectomy for benign conditions in a university hospital inHysterectomy for benign conditions in a university hospital in
Hysterectomy for benign conditions in a university hospital in
Tariq Mohammed
 
Improved diagnosis and prognosis using Decisions Informed by Combining Entiti...
Improved diagnosis and prognosis using Decisions Informed by Combining Entiti...Improved diagnosis and prognosis using Decisions Informed by Combining Entiti...
Improved diagnosis and prognosis using Decisions Informed by Combining Entiti...
Cardiovascular Diagnosis and Therapy (CDT)
 
Apsr bjm
Apsr bjmApsr bjm
The effect of clonidine on peri operative neuromuscular blockade and recovery
The effect of clonidine on peri operative neuromuscular blockade and recoveryThe effect of clonidine on peri operative neuromuscular blockade and recovery
The effect of clonidine on peri operative neuromuscular blockade and recovery
Ahmad Ozair
 
Kwon et.al
Kwon et.alKwon et.al
5 year follow-up
5 year follow-up5 year follow-up
5 year follow-up
Boris Maizel
 
Complication Rates Following Open Reduction and Internal Fixation of Ankle Fr...
Complication Rates Following Open Reduction and Internal Fixation of Ankle Fr...Complication Rates Following Open Reduction and Internal Fixation of Ankle Fr...
Complication Rates Following Open Reduction and Internal Fixation of Ankle Fr...
Ortopedia Chiapas
 
Comparison of 2 ntdb studies
Comparison of 2 ntdb studiesComparison of 2 ntdb studies
Comparison of 2 ntdb studies
nswhems
 
EVIDENCE OF POSTTRAUMATIC COAGULOPATHY IN CASE OF THE SEVERE COMBINED THORACI...
EVIDENCE OF POSTTRAUMATIC COAGULOPATHY IN CASE OF THE SEVERE COMBINED THORACI...EVIDENCE OF POSTTRAUMATIC COAGULOPATHY IN CASE OF THE SEVERE COMBINED THORACI...
EVIDENCE OF POSTTRAUMATIC COAGULOPATHY IN CASE OF THE SEVERE COMBINED THORACI...
pijans
 
Jco 2010-rizzo-jco.2010.29.2201
Jco 2010-rizzo-jco.2010.29.2201Jco 2010-rizzo-jco.2010.29.2201
Jco 2010-rizzo-jco.2010.29.2201
Clinica de imagenes
 
Burt_MS
Burt_MSBurt_MS
Donor Lymphocyte Infusion in Patients with Hematological Malignancies after T...
Donor Lymphocyte Infusion in Patients with Hematological Malignancies after T...Donor Lymphocyte Infusion in Patients with Hematological Malignancies after T...
Donor Lymphocyte Infusion in Patients with Hematological Malignancies after T...
spa718
 
Austin Journal of Clinical Cardiology
Austin Journal of Clinical CardiologyAustin Journal of Clinical Cardiology
Austin Journal of Clinical Cardiology
Austin Publishing Group
 
Donor Lymphocyte Infusion: Dr. Chenhua Yan
Donor Lymphocyte Infusion: Dr. Chenhua YanDonor Lymphocyte Infusion: Dr. Chenhua Yan
Donor Lymphocyte Infusion: Dr. Chenhua Yan
spa718
 
Traumagram Spring 2017
Traumagram Spring 2017Traumagram Spring 2017
Traumagram Spring 2017
Melissa Smith
 
Management of pediatric blunt renal trauma a systematic review
Management of pediatric blunt renal trauma  a systematic reviewManagement of pediatric blunt renal trauma  a systematic review
Management of pediatric blunt renal trauma a systematic review
skrentz
 
Derivation and validation of an exclusive pre operative risk evaluation syste...
Derivation and validation of an exclusive pre operative risk evaluation syste...Derivation and validation of an exclusive pre operative risk evaluation syste...
Derivation and validation of an exclusive pre operative risk evaluation syste...
Clinical Surgery Research Communications
 
Outcomes of Fibrinolytic Therapy Versus PCI
Outcomes of Fibrinolytic Therapy Versus PCIOutcomes of Fibrinolytic Therapy Versus PCI
Outcomes of Fibrinolytic Therapy Versus PCI
Peachy Essay
 
Intestinal resection in children our experience in enugu, nigeria
Intestinal resection in children   our experience in enugu, nigeriaIntestinal resection in children   our experience in enugu, nigeria
Intestinal resection in children our experience in enugu, nigeria
Clinical Surgery Research Communications
 
Journal club 1
Journal club 1Journal club 1
Journal club 1
Bhargav Kiran
 

What's hot (20)

Hysterectomy for benign conditions in a university hospital in
Hysterectomy for benign conditions in a university hospital inHysterectomy for benign conditions in a university hospital in
Hysterectomy for benign conditions in a university hospital in
 
Improved diagnosis and prognosis using Decisions Informed by Combining Entiti...
Improved diagnosis and prognosis using Decisions Informed by Combining Entiti...Improved diagnosis and prognosis using Decisions Informed by Combining Entiti...
Improved diagnosis and prognosis using Decisions Informed by Combining Entiti...
 
Apsr bjm
Apsr bjmApsr bjm
Apsr bjm
 
The effect of clonidine on peri operative neuromuscular blockade and recovery
The effect of clonidine on peri operative neuromuscular blockade and recoveryThe effect of clonidine on peri operative neuromuscular blockade and recovery
The effect of clonidine on peri operative neuromuscular blockade and recovery
 
Kwon et.al
Kwon et.alKwon et.al
Kwon et.al
 
5 year follow-up
5 year follow-up5 year follow-up
5 year follow-up
 
Complication Rates Following Open Reduction and Internal Fixation of Ankle Fr...
Complication Rates Following Open Reduction and Internal Fixation of Ankle Fr...Complication Rates Following Open Reduction and Internal Fixation of Ankle Fr...
Complication Rates Following Open Reduction and Internal Fixation of Ankle Fr...
 
Comparison of 2 ntdb studies
Comparison of 2 ntdb studiesComparison of 2 ntdb studies
Comparison of 2 ntdb studies
 
EVIDENCE OF POSTTRAUMATIC COAGULOPATHY IN CASE OF THE SEVERE COMBINED THORACI...
EVIDENCE OF POSTTRAUMATIC COAGULOPATHY IN CASE OF THE SEVERE COMBINED THORACI...EVIDENCE OF POSTTRAUMATIC COAGULOPATHY IN CASE OF THE SEVERE COMBINED THORACI...
EVIDENCE OF POSTTRAUMATIC COAGULOPATHY IN CASE OF THE SEVERE COMBINED THORACI...
 
Jco 2010-rizzo-jco.2010.29.2201
Jco 2010-rizzo-jco.2010.29.2201Jco 2010-rizzo-jco.2010.29.2201
Jco 2010-rizzo-jco.2010.29.2201
 
Burt_MS
Burt_MSBurt_MS
Burt_MS
 
Donor Lymphocyte Infusion in Patients with Hematological Malignancies after T...
Donor Lymphocyte Infusion in Patients with Hematological Malignancies after T...Donor Lymphocyte Infusion in Patients with Hematological Malignancies after T...
Donor Lymphocyte Infusion in Patients with Hematological Malignancies after T...
 
Austin Journal of Clinical Cardiology
Austin Journal of Clinical CardiologyAustin Journal of Clinical Cardiology
Austin Journal of Clinical Cardiology
 
Donor Lymphocyte Infusion: Dr. Chenhua Yan
Donor Lymphocyte Infusion: Dr. Chenhua YanDonor Lymphocyte Infusion: Dr. Chenhua Yan
Donor Lymphocyte Infusion: Dr. Chenhua Yan
 
Traumagram Spring 2017
Traumagram Spring 2017Traumagram Spring 2017
Traumagram Spring 2017
 
Management of pediatric blunt renal trauma a systematic review
Management of pediatric blunt renal trauma  a systematic reviewManagement of pediatric blunt renal trauma  a systematic review
Management of pediatric blunt renal trauma a systematic review
 
Derivation and validation of an exclusive pre operative risk evaluation syste...
Derivation and validation of an exclusive pre operative risk evaluation syste...Derivation and validation of an exclusive pre operative risk evaluation syste...
Derivation and validation of an exclusive pre operative risk evaluation syste...
 
Outcomes of Fibrinolytic Therapy Versus PCI
Outcomes of Fibrinolytic Therapy Versus PCIOutcomes of Fibrinolytic Therapy Versus PCI
Outcomes of Fibrinolytic Therapy Versus PCI
 
Intestinal resection in children our experience in enugu, nigeria
Intestinal resection in children   our experience in enugu, nigeriaIntestinal resection in children   our experience in enugu, nigeria
Intestinal resection in children our experience in enugu, nigeria
 
Journal club 1
Journal club 1Journal club 1
Journal club 1
 

Similar to Presentation

Haematology trials 2017
Haematology trials 2017Haematology trials 2017
Haematology trials 2017
Fadel Omar
 
D-dimer.full
D-dimer.fullD-dimer.full
D-dimer.full
Ryan Ramadhan
 
Factors determining outcomes in grown up patients operated
Factors determining outcomes in grown up patients operatedFactors determining outcomes in grown up patients operated
Factors determining outcomes in grown up patients operated
Dr. Murtaza Kamal MD,DNB,DrNB Ped Cardiology
 
Pd update nephro sudan 2017
Pd update nephro sudan  2017Pd update nephro sudan  2017
Pd update nephro sudan 2017
FarragBahbah
 
Metanlysis adjuvant pancreatic
Metanlysis adjuvant pancreaticMetanlysis adjuvant pancreatic
Metanlysis adjuvant pancreatic
Prof. Ahmed Mohamed Badheeb
 
Small cell lung cancer
Small cell lung cancerSmall cell lung cancer
Small cell lung cancer
redho1
 
Nov journal watch
Nov journal watchNov journal watch
Nov journal watch
katejohnpunag
 
HOLISTIC APPROACH
HOLISTIC APPROACHHOLISTIC APPROACH
HOLISTIC APPROACH
Kanhu Charan
 
Immunological and clinical assessment of adult hiv
Immunological and clinical assessment of adult hivImmunological and clinical assessment of adult hiv
Immunological and clinical assessment of adult hiv
MonaYuliari
 
Patients Of Size Nti
Patients Of Size NtiPatients Of Size Nti
Patients Of Size Nti
mgobl84462
 
DU PERF AND ABX
DU PERF AND ABX DU PERF AND ABX
DU PERF AND ABX
NHS
 
Wound dehiscence in surgical procedures and its relationship to increased mor...
Wound dehiscence in surgical procedures and its relationship to increased mor...Wound dehiscence in surgical procedures and its relationship to increased mor...
Wound dehiscence in surgical procedures and its relationship to increased mor...
AI Publications
 
Treatment and early outcome of 11 children with hepatoblastoma.
Treatment and early outcome of 11 children with hepatoblastoma.Treatment and early outcome of 11 children with hepatoblastoma.
Treatment and early outcome of 11 children with hepatoblastoma.
Dr./ Ihab Samy
 
Progression RA-ILD Poster ACR 2016 (Final Version)
Progression RA-ILD Poster ACR 2016 (Final Version)Progression RA-ILD Poster ACR 2016 (Final Version)
Progression RA-ILD Poster ACR 2016 (Final Version)
J.A. Zamora-Legoff
 
Oesophageal cancer osama
Oesophageal cancer osamaOesophageal cancer osama
Oesophageal cancer osama
Osama Elzaafarany, MD.
 
Risk stratification of scd
Risk stratification of scdRisk stratification of scd
Risk stratification of scd
Sunil Reddy D
 
E0342023026
E0342023026E0342023026
E0342023026
inventionjournals
 
Prognosis of pulmonary arterial hypertension
Prognosis of pulmonary arterial hypertensionPrognosis of pulmonary arterial hypertension
Prognosis of pulmonary arterial hypertension
gisa_legal
 
Otol HNS Better to be Young-2000-Lacy-Merritt
Otol HNS Better to be Young-2000-Lacy-MerrittOtol HNS Better to be Young-2000-Lacy-Merritt
Otol HNS Better to be Young-2000-Lacy-Merritt
Michael (Mick) Merritt
 
PPT Cath GAR 2.pptx
PPT Cath GAR 2.pptxPPT Cath GAR 2.pptx
PPT Cath GAR 2.pptx
ssusera752fd
 

Similar to Presentation (20)

Haematology trials 2017
Haematology trials 2017Haematology trials 2017
Haematology trials 2017
 
D-dimer.full
D-dimer.fullD-dimer.full
D-dimer.full
 
Factors determining outcomes in grown up patients operated
Factors determining outcomes in grown up patients operatedFactors determining outcomes in grown up patients operated
Factors determining outcomes in grown up patients operated
 
Pd update nephro sudan 2017
Pd update nephro sudan  2017Pd update nephro sudan  2017
Pd update nephro sudan 2017
 
Metanlysis adjuvant pancreatic
Metanlysis adjuvant pancreaticMetanlysis adjuvant pancreatic
Metanlysis adjuvant pancreatic
 
Small cell lung cancer
Small cell lung cancerSmall cell lung cancer
Small cell lung cancer
 
Nov journal watch
Nov journal watchNov journal watch
Nov journal watch
 
HOLISTIC APPROACH
HOLISTIC APPROACHHOLISTIC APPROACH
HOLISTIC APPROACH
 
Immunological and clinical assessment of adult hiv
Immunological and clinical assessment of adult hivImmunological and clinical assessment of adult hiv
Immunological and clinical assessment of adult hiv
 
Patients Of Size Nti
Patients Of Size NtiPatients Of Size Nti
Patients Of Size Nti
 
DU PERF AND ABX
DU PERF AND ABX DU PERF AND ABX
DU PERF AND ABX
 
Wound dehiscence in surgical procedures and its relationship to increased mor...
Wound dehiscence in surgical procedures and its relationship to increased mor...Wound dehiscence in surgical procedures and its relationship to increased mor...
Wound dehiscence in surgical procedures and its relationship to increased mor...
 
Treatment and early outcome of 11 children with hepatoblastoma.
Treatment and early outcome of 11 children with hepatoblastoma.Treatment and early outcome of 11 children with hepatoblastoma.
Treatment and early outcome of 11 children with hepatoblastoma.
 
Progression RA-ILD Poster ACR 2016 (Final Version)
Progression RA-ILD Poster ACR 2016 (Final Version)Progression RA-ILD Poster ACR 2016 (Final Version)
Progression RA-ILD Poster ACR 2016 (Final Version)
 
Oesophageal cancer osama
Oesophageal cancer osamaOesophageal cancer osama
Oesophageal cancer osama
 
Risk stratification of scd
Risk stratification of scdRisk stratification of scd
Risk stratification of scd
 
E0342023026
E0342023026E0342023026
E0342023026
 
Prognosis of pulmonary arterial hypertension
Prognosis of pulmonary arterial hypertensionPrognosis of pulmonary arterial hypertension
Prognosis of pulmonary arterial hypertension
 
Otol HNS Better to be Young-2000-Lacy-Merritt
Otol HNS Better to be Young-2000-Lacy-MerrittOtol HNS Better to be Young-2000-Lacy-Merritt
Otol HNS Better to be Young-2000-Lacy-Merritt
 
PPT Cath GAR 2.pptx
PPT Cath GAR 2.pptxPPT Cath GAR 2.pptx
PPT Cath GAR 2.pptx
 

Recently uploaded

DECLARATION OF HELSINKI - History and principles
DECLARATION OF HELSINKI - History and principlesDECLARATION OF HELSINKI - History and principles
DECLARATION OF HELSINKI - History and principles
anaghabharat01
 
Skin Diseases That Happen During Summer.
 Skin Diseases That Happen During Summer. Skin Diseases That Happen During Summer.
Skin Diseases That Happen During Summer.
Gokuldas Hospital
 
Lecture 6 -- Memory 2015.pptlearning occurs when a stimulus (unconditioned st...
Lecture 6 -- Memory 2015.pptlearning occurs when a stimulus (unconditioned st...Lecture 6 -- Memory 2015.pptlearning occurs when a stimulus (unconditioned st...
Lecture 6 -- Memory 2015.pptlearning occurs when a stimulus (unconditioned st...
AyushGadhvi1
 
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotesPromoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
PsychoTech Services
 
Ageing, the Elderly, Gerontology and Public Health
Ageing, the Elderly, Gerontology and Public HealthAgeing, the Elderly, Gerontology and Public Health
Ageing, the Elderly, Gerontology and Public Health
phuakl
 
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdfCHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
rishi2789
 
Recent advances on Cervical cancer .pptx
Recent advances on Cervical cancer .pptxRecent advances on Cervical cancer .pptx
Recent advances on Cervical cancer .pptx
DrGirishJHoogar
 
pharmacology for dummies free pdf download.pdf
pharmacology for dummies free pdf download.pdfpharmacology for dummies free pdf download.pdf
pharmacology for dummies free pdf download.pdf
KerlynIgnacio
 
NARCOTICS- POLICY AND PROCEDURES FOR ITS USE
NARCOTICS- POLICY AND PROCEDURES FOR ITS USENARCOTICS- POLICY AND PROCEDURES FOR ITS USE
NARCOTICS- POLICY AND PROCEDURES FOR ITS USE
Dr. Ahana Haroon
 
Acute Gout Care & Urate Lowering Therapy .pdf
Acute Gout Care & Urate Lowering Therapy .pdfAcute Gout Care & Urate Lowering Therapy .pdf
Acute Gout Care & Urate Lowering Therapy .pdf
Jim Jacob Roy
 
How to Control Your Asthma Tips by gokuldas hospital.
How to Control Your Asthma Tips by gokuldas hospital.How to Control Your Asthma Tips by gokuldas hospital.
How to Control Your Asthma Tips by gokuldas hospital.
Gokuldas Hospital
 
Demystifying Fallopian Tube Blockage- Grading the Differences and Implication...
Demystifying Fallopian Tube Blockage- Grading the Differences and Implication...Demystifying Fallopian Tube Blockage- Grading the Differences and Implication...
Demystifying Fallopian Tube Blockage- Grading the Differences and Implication...
FFragrant
 
Osteoporosis - Definition , Evaluation and Management .pdf
Osteoporosis - Definition , Evaluation and Management .pdfOsteoporosis - Definition , Evaluation and Management .pdf
Osteoporosis - Definition , Evaluation and Management .pdf
Jim Jacob Roy
 
vonoprazan A novel drug for GERD presentation
vonoprazan A novel drug for GERD presentationvonoprazan A novel drug for GERD presentation
vonoprazan A novel drug for GERD presentation
Dr.pavithra Anandan
 
Test bank for karp s cell and molecular biology 9th edition by gerald karp.pdf
Test bank for karp s cell and molecular biology 9th edition by gerald karp.pdfTest bank for karp s cell and molecular biology 9th edition by gerald karp.pdf
Test bank for karp s cell and molecular biology 9th edition by gerald karp.pdf
rightmanforbloodline
 
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
rishi2789
 
Cell Therapy Expansion and Challenges in Autoimmune Disease
Cell Therapy Expansion and Challenges in Autoimmune DiseaseCell Therapy Expansion and Challenges in Autoimmune Disease
Cell Therapy Expansion and Challenges in Autoimmune Disease
Health Advances
 
Pharmacology of 5-hydroxytryptamine and Antagonist
Pharmacology of 5-hydroxytryptamine and AntagonistPharmacology of 5-hydroxytryptamine and Antagonist
Pharmacology of 5-hydroxytryptamine and Antagonist
Dr. Nikhilkumar Sakle
 
Know the difference between Endodontics and Orthodontics.
Know the difference between Endodontics and Orthodontics.Know the difference between Endodontics and Orthodontics.
Know the difference between Endodontics and Orthodontics.
Gokuldas Hospital
 
Medical Quiz ( Online Quiz for API Meet 2024 ).pdf
Medical Quiz ( Online Quiz for API Meet 2024 ).pdfMedical Quiz ( Online Quiz for API Meet 2024 ).pdf
Medical Quiz ( Online Quiz for API Meet 2024 ).pdf
Jim Jacob Roy
 

Recently uploaded (20)

DECLARATION OF HELSINKI - History and principles
DECLARATION OF HELSINKI - History and principlesDECLARATION OF HELSINKI - History and principles
DECLARATION OF HELSINKI - History and principles
 
Skin Diseases That Happen During Summer.
 Skin Diseases That Happen During Summer. Skin Diseases That Happen During Summer.
Skin Diseases That Happen During Summer.
 
Lecture 6 -- Memory 2015.pptlearning occurs when a stimulus (unconditioned st...
Lecture 6 -- Memory 2015.pptlearning occurs when a stimulus (unconditioned st...Lecture 6 -- Memory 2015.pptlearning occurs when a stimulus (unconditioned st...
Lecture 6 -- Memory 2015.pptlearning occurs when a stimulus (unconditioned st...
 
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotesPromoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
 
Ageing, the Elderly, Gerontology and Public Health
Ageing, the Elderly, Gerontology and Public HealthAgeing, the Elderly, Gerontology and Public Health
Ageing, the Elderly, Gerontology and Public Health
 
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdfCHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
 
Recent advances on Cervical cancer .pptx
Recent advances on Cervical cancer .pptxRecent advances on Cervical cancer .pptx
Recent advances on Cervical cancer .pptx
 
pharmacology for dummies free pdf download.pdf
pharmacology for dummies free pdf download.pdfpharmacology for dummies free pdf download.pdf
pharmacology for dummies free pdf download.pdf
 
NARCOTICS- POLICY AND PROCEDURES FOR ITS USE
NARCOTICS- POLICY AND PROCEDURES FOR ITS USENARCOTICS- POLICY AND PROCEDURES FOR ITS USE
NARCOTICS- POLICY AND PROCEDURES FOR ITS USE
 
Acute Gout Care & Urate Lowering Therapy .pdf
Acute Gout Care & Urate Lowering Therapy .pdfAcute Gout Care & Urate Lowering Therapy .pdf
Acute Gout Care & Urate Lowering Therapy .pdf
 
How to Control Your Asthma Tips by gokuldas hospital.
How to Control Your Asthma Tips by gokuldas hospital.How to Control Your Asthma Tips by gokuldas hospital.
How to Control Your Asthma Tips by gokuldas hospital.
 
Demystifying Fallopian Tube Blockage- Grading the Differences and Implication...
Demystifying Fallopian Tube Blockage- Grading the Differences and Implication...Demystifying Fallopian Tube Blockage- Grading the Differences and Implication...
Demystifying Fallopian Tube Blockage- Grading the Differences and Implication...
 
Osteoporosis - Definition , Evaluation and Management .pdf
Osteoporosis - Definition , Evaluation and Management .pdfOsteoporosis - Definition , Evaluation and Management .pdf
Osteoporosis - Definition , Evaluation and Management .pdf
 
vonoprazan A novel drug for GERD presentation
vonoprazan A novel drug for GERD presentationvonoprazan A novel drug for GERD presentation
vonoprazan A novel drug for GERD presentation
 
Test bank for karp s cell and molecular biology 9th edition by gerald karp.pdf
Test bank for karp s cell and molecular biology 9th edition by gerald karp.pdfTest bank for karp s cell and molecular biology 9th edition by gerald karp.pdf
Test bank for karp s cell and molecular biology 9th edition by gerald karp.pdf
 
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
 
Cell Therapy Expansion and Challenges in Autoimmune Disease
Cell Therapy Expansion and Challenges in Autoimmune DiseaseCell Therapy Expansion and Challenges in Autoimmune Disease
Cell Therapy Expansion and Challenges in Autoimmune Disease
 
Pharmacology of 5-hydroxytryptamine and Antagonist
Pharmacology of 5-hydroxytryptamine and AntagonistPharmacology of 5-hydroxytryptamine and Antagonist
Pharmacology of 5-hydroxytryptamine and Antagonist
 
Know the difference between Endodontics and Orthodontics.
Know the difference between Endodontics and Orthodontics.Know the difference between Endodontics and Orthodontics.
Know the difference between Endodontics and Orthodontics.
 
Medical Quiz ( Online Quiz for API Meet 2024 ).pdf
Medical Quiz ( Online Quiz for API Meet 2024 ).pdfMedical Quiz ( Online Quiz for API Meet 2024 ).pdf
Medical Quiz ( Online Quiz for API Meet 2024 ).pdf
 

Presentation

  • 1. RATES AND TIMING OF SUBSEQUENT AMPUTATION AFTER INITIAL MINOR AMPUTATION
  • 2.
  • 3. Introduction Major amputation is a significant concern for patients who have undergone a minor amputation due to diabetes mellitus (DM) and/or peripheral artery disease (PAD). Fear a major amputation than to fear death (Wukich et al). Only 55% of patients with a below-the-knee amputation and 45% of those with an above-the-knee amputation report a good functional outcome. The rate of major amputation after initial minor amputation varies from 14% to 35%
  • 4. METHODS A retrospective cohort study using all-payer statewide data from OSHPD between 2005 and 2013. The Institutional Review Boards for the California Health and Welfare Agency (Committee for the Protection of Human Subjects) approved this study and waived consent given the retrospective nature of the study.
  • 5. Database The California OSHPD database captures all nonfederal inpatient hospitalizations. The OSHPD collects data from all emergency departments and from eligible ambulatory surgery centers Nonfederal hospitals account for 96% of the hospitals in California. Records for each patient in the OSHPD database are linked through an encrypted Social Security Number called the Record Linkage Number.
  • 6. Within the PDD and EDD, medical diagnoses and procedures were coded using (ICD-9-CM). All patients admitted to the hospital are captured as a part of the PDD and had their therapy administered on an inpatient basis. Patient was first evaluated in the emergency department and discharged. Patients that initially presented to the emergency room are part of the EDD.
  • 7.
  • 8. The ASD procedures are coded using Current ProcedureTerminology code The primary end point was major amputation, defined as a below knee or an above knee amputation and was identified by ICD-9-CM codes. The secondary end points include time to major amputation, repeat minor amputation, time to repeat minor amputation, overall mortality, time to death, and the combined outcome of amputation or death. Additional analysis was performed to examine how timing of revascularization and location of initial presentation were associated with risk of subsequent major amputation.
  • 9.
  • 10. Comorbidity data The Elixhauser comorbidity software was used to define comorbidities; DM and PAD were excluded Additional comorbid conditions were captured using data provided by the secondary diagnosis codes, such as coronary artery disease, congestive heart failure, renal failure, and tobacco use
  • 11. StatisticalAnalysis For categorical variables, the three distinct disease groups were compared using the X2 test. Frequencies and percentages were used for categorical variables. Medians and interquartile ranges (IQRs) were used to describe skewed continuous data. Means and standard deviations were used to describe normally distributed continuous variables. Rates were determined by the number of patients who underwent major amputation divided by the number of patients in each disease category and reported as a percentage.
  • 12. For continuous variables, the groups were compared using a pairwise t-test with Bonferroni adjustment. Competing risk Cox proportional hazards analysis was used to evaluate for risk factors associated with major amputation. All analyses were performed using R Programming for Statistical Analysis (The R Foundation,Vienna, Austria). A P value of less than .05 was considered statistically significant.
  • 13. Baseline characteristics varied significantly between the three disease groups (Table I). Patients in the combined PAD/DM group had more comorbidities with a higher prevalence of coronary artery disease, congestive heart failure, and renal failure. The patients with DM alone tended to be younger with an average age of 62 6 13 years old, whereas there were more smokers (PAD 1⁄4 20%, DM 1⁄4 10%, PAD/DM 1⁄4 10%; P < .001) and white patients (PAD 1⁄4 52% DM 1⁄4 40%, PAD/DM 1⁄4 35%; P < .001) in the PAD only group. Patients with DM alone were the least likely to undergo any revascularization procedure during the study period (DM 1⁄4 75% no revascularization, PAD 1⁄4 64%, PAD/DM 1⁄4 63%; P < .001).
  • 14. Rate of subsequent amputation The overall rate of major amputation in the cohort was 5.1% (n 1⁄4 594) and the rate of repeat minor amputation was 14.5% (n 1⁄4 1676). Patients with combined PAD/DM were more likely to undergo major amputation (n 1⁄4 327 [6.3%]) compared with patients with DM (n 1⁄4 223 [5.2%]) or PAD alone (n 1⁄4 44 [2.1%]; P < .001). Patients in the PAD/DM group were also more likely to require a second minor amputation as well (PAD/DM 1⁄4 16%, DM 1⁄4 12.2%, PAD 1⁄4 15.2%; P < .001;Table II).
  • 15. Time to subsequent amputation. The median time to a second minor amputation was 4.9 months (IQR, 1.8-14.7 months). Patients with DM had a longer time be- tween the initial minor amputation and the second mi- nor amputation (5.9 months; IQR, 2.1-17 months; P < .01), whereas patients with PAD and PAD/DM were more likely to require a second minor amputation sooner, with both groups having a median time of 4.5 months (PAD IQR, 1.5-15 months; PAD/DM IQR, 1.8-13 months).The median time to major amputation for all patients was 12.9 months (IQR, 5.4-27.6 months).There was no statistically significant difference in time
  • 16. Major amputation between patients in the three groups, but patients with PAD only had a median time to major amputation of 8.6 months (IQR, 4.2-23.4 months) compared with patients with DM at 14.1 (IQR, 5.6-33.1 months) and PAD/DM at 13.3 months (IQR, 5.5- 25.3; Table II).
  • 17. Mortality • The overall mortality for the entire cohort was high at 46.7% (Fig 2). Patients in the DM only group had the lowest mortality at 41% compared with 52% in the PAD only group and 49% in the combined PAD/DM group. As shown inTable II, the median time to death for patients in the DM only group was longest at 17.6 months (1.5 years; IQR, 7.1- 35.3 months). Patients with PAD had the shortest time to death at 10 months (0.8 years; IQR, 4.4-25.4 months).The median time to death for patients with combined PAD/DM was 13.3 months (1.1 years; IQR, 5.3-32.6 months; P < .001). Revascularization • In 63% of patients with known PAD and 64% of patients with PAD/DM, no revascularization was attempted before subsequent major amputation was performed. After adjusting for age, race, sex, payer status, and associated comorbid conditions, there was
  • 18.
  • 19.
  • 20. CONCLUSIONS Despite these limitations, the data illustrate that patients with lower extremity wounds who require any amputation have multiple comorbidities and have a high mortality rate. A number of these patients, especially those with combined PAD and DM, will require a subsequent major amputation in approximately 1 year after their initial minor amputation. Furthermore, the lower risk of subsequent limb loss in patients who were revascularized before another minor amputation and those who were evaluated and treated entirely on an outpatient basis suggests that there is a benefit in early diagnosis and therapy. Future work should aim to evaluate the effect of time to treatment on patient outcomes.